A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia

被引：13

作者：

Francis, Sebastian ^{[1
]}

Lucas, Claire ^{[1
]}

Lane, Steven ^{[1
]}

Wang, Lihui ^{[1
]}

Watmough, Sarah ^{[1
]}

Knight, Katy ^{[1
]}

Bell, Jo ^{[1
]}

Kaleel-Rahman, Mohammed ^{[2
]}

Lee, Edwin ^{[3
]}

O'Brien, David ^{[4
]}

Butt, Nauman M. ^{[5
]}

Sadik, Walid ^{[6
]}

De Soysa, Lally ^{[7
]}

Seale, Jim R. C. ^{[8
]}

Salim, Rahuman ^{[1
]}

Clark, Richard E. ^{[1
]}

机构：

[1] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[2] Warrington Hosp, Dept Haematol, Warrington, Cheshire, England

[3] Countess Chester Hosp, Dept Haematol, Chester, Cheshire, England

[4] Southport Dist Gen Hosp, Dept Haematol, Richmond, Southport, England

[5] Arrowe Pk Hosp, Dept Haematol, Wirral, Merseyside, England

[6] Aintree Univ Hosp NHS Fdn Trust, Dept Haematol, Liverpool L9 7AL, Merseyside, England

[7] Wrexham Maelor Hosp, Dept Haematol, Wrexham, Wales

[8] Ysbyty Gwynedd Hosp, Alaw Unit, Bangor, Gwynedd, Wales

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 07期

关键词：

Chronic myeloid leukaemia; Tyrosine kinase inhibitors; Dasatinib; Nilotinib; IMATINIB; DASATINIB; RESPONSES; FAILURE;

D O I：

10.1016/j.leukres.2013.04.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: Population based data suggest the proportion of patients failing imatinib in chronic myeloid leukaemia (CML) is higher than the reported one-third of patients in clinical trials. Clinical trials have demonstrated second generation tyrosine kinase inhibitors (TKI) dasatinib and nilotinib can restore complete cytogenetic remission (CCR) and major molecular response (MMR) to many patients failing imatinib, but their impact in the general population is not clear. Design and methods: We report CML outcome in a population of 2.3 million people in a geographically contiguous area of North West England and North Wales. Results: Between 2003 and 2009, 192 new CML cases were diagnosed, of whom 184 were in chronic phase and 160 started on imatinib. The maximal CCR rate was 65% at 24 months and the maximal MMR rate was 50% at 36 months. Patients diagnosed since second generation TKI became available for imatinib failure had a more rapid cumulative CCR and MMR rate and a significantly improved progression free survival (p = 0.022) than those diagnosed before this time. Conclusion: The study indicates that second generation TKI have improved CML outcome in the general population. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：752 / 758

页数：7

共 11 条

[1]

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[2]

Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].

de Lavallade, Hugues ;

Apperley, Jane F. ;

Khorashad, Jamshid S. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363

[3]

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study [J].

Gallipoli, Paolo ;

Shepherd, Pat ;

Irvine, David ;

Drummond, Mark ;

Holyoake, Tessa .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (01) :128-130

[4]

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value [J].

Hochhaus, A. ;

Mueller, M. C. ;

Radich, J. ;

Branford, S. ;

Kantarjian, H. M. ;

Hanfstein, B. ;

Rousselot, P. ;

Kim, D-W ;

Lipton, J. H. ;

Bleickardt, E. ;

Lambert, A. ;

Hughes, T. P. .

LEUKEMIA, 2009, 23 (09) :1628-1633

[5]

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial [J].

Kantarjian, Hagop ;

Pasquini, Ricardo ;

Hamerschlak, Nelson ;

Rousselot, Philippe ;

Holowiecki, Jerzy ;

Jootar, Saengsuree ;

Robak, Tadeusz ;

Khoroshko, Nina ;

Masszi, Tamas ;

Skotnicki, Aleksander ;

Hellmann, Andrzej ;

Zaritsky, Andrey ;

Golenkov, Anatoly ;

Radich, Jerald ;

Hughes, Timothy ;

Countouriotis, Athena ;

Shah, Neil .

BLOOD, 2007, 109 (12) :5143-5150

[6]

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results [J].

Kantarjian, Hagop M. ;

Giles, Francis J. ;

Bhalla, Kapil N. ;

Pinilla-Ibarz, Javier ;

Larson, Richard A. ;

Gattermann, Norbert ;

Ottmann, Oliver G. ;

Hochhaus, Andreas ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Hughes, Timothy P. ;

Martinelli, Giovanni ;

Kim, Dong-Wook ;

Shou, Yaping ;

Gallagher, Neil J. ;

Blakesley, Rick ;

Baccarani, Michele ;

Cortes, Jorge ;

le Coutre, Philipp D. .

BLOOD, 2011, 117 (04) :1141-1145

[7]

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials [J].

Lucas, C. M. ;

Wang, L. ;

Austin, G. M. ;

Knight, K. ;

Watmough, S. J. ;

Shwe, K. H. ;

Dasgupta, R. ;

Butt, Nauman M. ;

Galvani, D. ;

Hoyle, C. F. ;

Seale, J. R. C. ;

Clark, R. E. .

LEUKEMIA, 2008, 22 (10) :1963-1966

[8]

O'Brien SG, 2008, BLOOD, V112, P76

[9]

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia [J].

Saglio, Giuseppe ;

Kim, Dong-Wook ;

Issaragrisil, Surapol ;

le Coutre, Philipp ;

Etienne, Gabriel ;

Lobo, Clarisse ;

Pasquini, Ricardo ;

Clark, Richard E. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Gallagher, Neil ;

Hoenekopp, Albert ;

Dong, Mei ;

Haque, Ariful ;

Larson, Richard A. ;

Kantarjian, Hagop M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2251-2259

[10]

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias [J].

Talpaz, Moshe ;

Shah, Neil P. ;

Kantarjian, Hagop ;

Donato, Nicholas ;

Nicoll, John ;

Paquette, Ron ;

Cortes, Jorge ;

O'Brien, Susan ;

Nicaise, Claude ;

Bleickardt, Eric ;

Blackwood-Chirchir, M. Anne ;

Iyer, Vishwanath ;

Chen, Tai-Tsang ;

Huang, Fei ;

Decillis, Arthur P. ;

Sawyers, Charles L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2531-2541

← 1 2 →